Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.64 |
| ▸ | TLR2 | O60603 | 4/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | EPOR | P19235 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29336336 | 0.98 | GLP1R (0.66) | GLP1RTLR2NOD1FOLH1LPAR3 | |
| SCHEMBL24630187 | 0.91 | GLP1R (0.55) | GLP1RFOLH1 | |
| SCHEMBL29329023 | 0.90 | GLP1R (0.56) | GLP1RTLR2FOLH1EPORNMT2 | |
| SCHEMBL24630309 | 0.89 | GLP1R (0.56) | GLP1RTLR2FOLH1LPAR3 | |
| SCHEMBL29328877 | 0.87 | GLP1R (0.58) | GLP1RTLR2NOD1FOLH1EPOR | |
| SCHEMBL26346478 | 0.87 | GLP1R (0.60) | GLP1RTLR2NOD1LPAR3 | |
| SCHEMBL30094802 | 0.86 | GLP1R (0.59) | GLP1RTLR2NMT2NMT1 | |
| SCHEMBL29727801 | 0.85 | GLP1R (0.52) | GLP1RFOLH1 | |
| SCHEMBL24630021 | 0.85 | GLP1R (0.52) | GLP1RFOLH1 | |
| SCHEMBL24668378 | 0.85 | GLP1R (0.57) | GLP1RTLR2FOLH1EPORNMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | GLP1R 2531/4885TLR2 164/4885NOD1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.